Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

Dapirolizumab is an investigational product in clinical development.  The safety and efficacy have not been established and it is not approved by the Food and Drug Administration, or by any health authority worldwide.  The material below is provided in response to your specific search for information on UCBCOMPASS®.  It is not intended to draw any conclusion regarding the efficacy and safety of dapirolizumab for any indication, dosage, or other claim.